BridgeMD
New treatment option for Obesity
Official title Pharmacogenetics of Response to GLP1R Agonists
ClinicalTrials.gov ID: NCT05071898
What this study is testing
What is Semaglutide Pen Injector [Ozempic]?
Semaglutide Pen Injector [Ozempic] is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for obesity.
Also referred to as Ozempic, Wegovy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 89. Healthy volunteers may be eligible.
You may be able to join if
- BMI greater than or equal to 27 kg/m2
- Of Amish Descent
You likely can't join if
- Woman of childbearing age who is sexually active
- History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL)
- Known allergy to semaglutide
- Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
- eGFR \< 60 mL/min/1.73 sq. m.
- Hematocrit \< 35%
See the full eligibility criteria
- BMI greater than or equal to 27 kg/m2
- Of Amish Descent
- Woman of childbearing age who is sexually active
- History of diabetes (HbA1c \> 6.5% or random glucose \>200 mg/dL)
- Known allergy to semaglutide
- Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
- eGFR \< 60 mL/min/1.73 sq. m.
- Hematocrit \< 35%
- TSH \ 5.5
- AST or ALT in excess of 2X the upper limit of normal
- Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
- Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
The study team makes the final eligibility decision.
Where it's taking place
- Lancaster, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 89 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lancaster, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.